Back

Nonalcoholic fatty liver disease worsens cardiac repair after myocardial infarction

30 August 2024 (14:00 - 14:40)
Organised by: Logo
Congress Presentation Part of: Basic research in acute coronary syndromes Left Ventricular Remodelling ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Feriel Hamidou

Paris (France)

5 More presentations in this session

Presentation thumbnail
Empagliflozin treatment pre- and post- acute myocardial infarction reduces no-reflow, inflammatory cell infiltration and infarct size while preserving cardiac function.
Doctor P. Nikolaou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Carvedilol suppresses coronary artery spasm in A-kinase anchoring protein 150 knockout mouse
Doctor Y. Konno (Hirosaki, JP)
Abstract Slides Video
Presentation thumbnail
Mortality related to left ventricular ejection fraction and obstructive coronary artery disease in non-ST-segment elevation myocardial infarction
Doctor N. Stoedkilde-Joergensen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
TLR7 deficiency alleviated myocardial ischemia reperfusion injury via regulating macrophage-neutrophil interaction
Doctor Y. Lai (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Soluble amyloid precursor protein-alpha mediates post-ischemic neovascularization after myocardial infarction
Doctor H. Kawase (Bad Nauheim, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Basic research in acute coronary syndromes

The Event

Event poster

ESC Congress 2024

30 August 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic outcomes of masld and obesity in acute myocardial infarction
thumbnail
Congress Presentation
The prognostic value of metabolic dysfunction associated steatotic liver disease in acute myocardial infarction
thumbnail
Congress Presentation
The effect of 6-month treatment with coenzyme Q10 on endothelial, vascular and myocardial function in patients with nonalcoholic fatty liver disease.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources